Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 259,643
  • Shares Outstanding, K 58,876
  • Annual Sales, $ 0 K
  • Annual Income, $ -73,790 K
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.58
Trade PYXS with:

Options Overview Details

View History
  • Implied Volatility 133.84% ( +0.07%)
  • Historical Volatility 109.23%
  • IV Percentile 42%
  • IV Rank 16.52%
  • IV High 656.63% on 12/27/23
  • IV Low 30.35% on 06/15/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 108
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 2,502
  • Open Int (30-Day) 3,310

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 3
  • High Estimate -0.17
  • Low Estimate -0.32
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +53.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.06 +14.53%
on 04/19/24
5.88 -20.92%
on 04/04/24
-0.92 (-16.52%)
since 04/03/24
3-Month
3.35 +38.81%
on 02/05/24
6.85 -32.12%
on 02/27/24
+0.97 (+26.36%)
since 02/02/24
52-Week
1.35 +244.44%
on 11/24/23
6.85 -32.12%
on 02/27/24
+1.72 (+58.70%)
since 05/03/23

Most Recent Stories

More News
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END

ONCY : 1.1800 (+0.85%)
ONC.TO : 1.61 (+1.26%)
PYXS : 4.68 (+6.12%)
AZN : 75.94 (+0.18%)
LLY : 738.20 (-2.34%)
MRUS : 48.38 (+1.85%)
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

/PRNewswire/ -- USA News Group - Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy...

ONC.TO : 1.61 (+1.26%)
ONCY : 1.1800 (+0.85%)
PYXS : 4.68 (+6.12%)
AZN : 75.94 (+0.18%)
LLY : 738.20 (-2.34%)
MRUS : 48.38 (+1.85%)
Breakthroughs in Pancreatic Cancer Treatment: How FDA Designations are Changing the Game

USA News Group – Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the...

ONCY : 1.1800 (+0.85%)
ONC.TO : 1.61 (+1.26%)
PYXS : 4.68 (+6.12%)
AZN : 75.94 (+0.18%)
LLY : 738.20 (-2.34%)
MRUS : 48.38 (+1.85%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

PYXS : 4.68 (+6.12%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ: PYXS)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ: PYXS) concerning possible breaches of...

PYXS : 4.68 (+6.12%)
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation...

PYXS : 4.68 (+6.12%)
NIRI Chicago Elects 2022-2023 Officers and Directors

The Chicago Chapter of the National Investor Relations Institute (NIRI Chicago) has elected 12 officers and directors to its board for the 2022-2023 term, effective July 1.

UNVR : 36.14 (+0.47%)
WEBR : 8.12 (unch)
PTLO : 11.97 (+0.25%)
MEI : 12.25 (-0.16%)
ACCO : 4.91 (-0.20%)
ZBRA : 310.18 (-0.81%)
BY : 23.04 (+1.05%)
GCMG : 9.66 (+0.42%)
HZNP : 116.30 (+0.04%)
CF : 74.10 (+0.31%)
CTSO : 0.9000 (+9.84%)
PYXS : 4.68 (+6.12%)
Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference

CAMBRIDGE, Mass., June 28, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), an oncology company focused on developing next-generation...

PYXS : 4.68 (+6.12%)
Pyxis Oncology Announces Presentations at Upcoming Investor Conferences

CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing...

PYXS : 4.68 (+6.12%)
Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update

CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing...

PYXS : 4.68 (+6.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 4.66
2nd Resistance Point 4.57
1st Resistance Point 4.49
Last Price 4.68
1st Support Level 4.32
2nd Support Level 4.23
3rd Support Level 4.15

See More

52-Week High 6.85
Fibonacci 61.8% 4.75
Last Price 4.68
Fibonacci 50% 4.10
Fibonacci 38.2% 3.45
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar